M2 Archive: Preview
You haven't logged in. If you have archive credits in your account, please log in now to use them. If not, you can buy credits in our shopping area.
Ningbo Tai Kang Medical Technology Co Ltd awarded exclusive global rights to AZD3229
Chinese oncology company Ningbo Tai Kang Medical Technology Co Ltd revealed on Friday that it has entered into an agreement with AstraZeneca to acquire the exclusive global rights to further develop and commercialize AZD3229.
According to the company, AZD3229 is a small molecule inhibitor...
If you want to view the full text of this story, you must first purchase archive credits. Return to Archives
New Search